The Peptides That Actually Passed the Test
Most of the peptide world runs on animal studies, forum anecdotes, and optimism. GLP-1 receptor agonists are the exception. They are peptide-based drugs that went through large, multi-year, placebo-controlled trials, earned regulatory approval, and produced some of the biggest weight-loss effects ever recorded for a medication.
If you are comparing "peptides for weight loss," this is the category where the evidence is strongest by a wide margin. It is also the category where the gray market is most dangerous, because the stakes (and the price tag) are high.
How GLP-1 Drugs Work
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your brain you are full, slows the emptying of your stomach, and helps your pancreas release insulin when blood sugar rises. Natural GLP-1 is broken down within minutes. The drugs in this class are engineered versions that last long enough to be dosed weekly (or even daily orally).
The effect is not a "metabolism boost." It is mostly an appetite effect: less food noise, earlier fullness, and smaller portions without the same willpower fight. That distinction matters for what happens when you stop.
The Main Options Compared
| Drug | Mechanism | Brand names | Status | Typical trial weight loss |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Ozempic, Wegovy, Rybelsus | FDA-approved | ~15% |
| Tirzepatide | GIP + GLP-1 | Mounjaro, Zepbound | FDA-approved | up to ~22% |
| Liraglutide | GLP-1 | Victoza, Saxenda | FDA-approved | ~5-8% |
| CagriSema | Amylin + GLP-1 | In review | Not yet approved | ~20% (Phase 3) |
| Retatrutide | GLP-1 + GIP + glucagon | None | Not approved | ~28% (Phase 3) |
| Survodutide | Glucagon + GLP-1 | None | Not approved | ~17-19% |
Weight-loss figures are averages from the pivotal trials in each profile, measured at different durations and in different populations. They are a guide, not a promise: individual results vary widely.
Semaglutide
The drug that made the category famous. Large trials showed roughly 15% average weight loss and a cardiovascular benefit in people with existing heart disease. Available as a weekly injection and, in lower-dose form, as a daily pill.
Tirzepatide
Adds a second hormone target (GIP). In head-to-head trials it has outperformed semaglutide on weight loss. It is the current efficacy leader among approved options.
Liraglutide
The older, daily-injection predecessor. Effective but less so than newer drugs, and now mostly relevant as a lower-cost or generic option.
The Next Generation
The pipeline is moving toward hitting more than one hormone pathway at once:
- [Retatrutide](/peptides/retatrutide/) adds glucagon receptor activation to GLP-1 and GIP. Phase III trials have reported average losses near 28% at the top dose. It is not yet approved.
- [CagriSema](/peptides/cagrilintide/) pairs semaglutide with the amylin analog cagrilintide. Phase III data showed about 20% weight loss, and an FDA decision is expected.
- [Survodutide](/peptides/survodutide/) combines glucagon and GLP-1 activity and is also being studied for fatty liver disease (MASH).
"Not yet approved" matters. Anything labeled retatrutide that you can buy today is not a pharmaceutical product. See the gray-market section below.
The Part Nobody Puts in the Ad
Side effects are common
Nausea, vomiting, diarrhea, and constipation are the norm, especially during dose escalation. Most people find these ease with time, but a meaningful number stop treatment because of them. Rarer but serious risks include pancreatitis and gallbladder problems.
Muscle loss is real
Rapid weight loss takes lean mass along with fat. Adequate protein and resistance training meaningfully reduce this, and they are the most underrated part of any GLP-1 plan.
Stopping usually means regaining
Because the effect is largely appetite suppression, weight tends to return after discontinuation unless habits have changed. Most clinicians now treat these drugs as long-term therapy for a chronic condition, not a short course.
Cost and access
Without insurance coverage, monthly cost can run into the high hundreds or more. That price gap is the entire reason a compounded and gray market exists.
Compounded and Gray-Market GLP-1s
This is where the risk concentrates.
- Compounded semaglutide and tirzepatide boomed during official drug shortages. The shortage-based allowances have since ended, and regulators have moved to restrict most compounding of these drugs. Earlier safety reports documented dosing errors with compounded products, partly because vials and syringes use different units than the branded pens.
- "Research use only" retatrutide and similar is sold with no regulatory oversight at all. Independent testing of gray-market peptides has repeatedly found wrong concentrations, contaminants, and mislabeled contents. For a drug you inject weekly, that is a poor bet.
- Oral "GLP-1 peptide" supplements that claim to match the injectables have no comparable evidence. Peptides are generally destroyed by digestion, and the approved oral products rely on specific formulation technology.
If a product is much cheaper than the approved version, ask what you are not being told: the source of the active ingredient, the testing, the sterility, and who is accountable if something goes wrong. Our guide to how to evaluate peptide quality walks through the questions to ask.
Who These Drugs Are For
Approved indications generally center on obesity (or overweight with a related condition) and type 2 diabetes. They are not designed for losing the last few pounds before a vacation, and they are not appropriate for everyone. Pregnancy, certain thyroid cancer histories, and some pancreatic conditions are common reasons a physician would say no.
Practical Takeaways
- GLP-1 drugs are the best-evidenced peptide therapies available. Large trials, real outcomes, regulatory approval
- Tirzepatide currently leads on efficacy among approved options, and the pipeline (retatrutide, CagriSema, survodutide) is pushing further
- They require a prescriber. Monitoring, dose escalation, and screening for contraindications are part of the safety model
- Plan for protein and strength training to protect muscle, and plan for the long term rather than a short course
- Avoid gray-market and unapproved versions. An unapproved drug from an unaccountable source is not a cost saving if it harms you
- Do not start or stop any of these without a physician. This guide is educational, not medical advice